Fig. 3

In vitro BBB penetration and neuroprotective efficacy of SCU@AMExo. (A) Representative fluorescence microscopy images about cellular uptake behaviors of different C6-labeled nanoparticles in bEnd.3 cells. (Scale bars:100 μm) (B) Semi-quantification of cellular uptake for C6-labeled nanoparticles in bEnd.3 cells (n = 3). (C) Schematic diagram of the in vitro BBB model. (D) In vitro BBB permeability in transwell model (n = 5). (E) Cell viability of PC12 cells with OGD/R injury after treatment with different concentrations of SCU@AMExo (n = 5). (F) Live/Dead staining of PC12 cells with OGD/R injury following different treatments (Scale bars:100 μm). (G) The Semi-quantitative analysis of the ratio of live cells in live/dead cell staining (n = 3). Data are presented as mean ± SD; n = 3, n = 5 means three or five biological replicates; ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001